Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 13/20 | 0.43 |
| ▸ | NOS3 | P29474 | 10/20 | 0.43 |
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | FPR2 | P25090 | 5/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220876 | 0.85 | CHEK1 (0.45) | NOS1NOS3NOS2FPR2SYK | |
| SCHEMBL221350 | 0.78 | NOS1 (0.67) | NOS1NOS3NOS2 | |
| SCHEMBL221745 | 0.77 | FPR2 (0.39) | NOS1NOS3NOS2FPR2 | |
| SCHEMBL221219 | 0.75 | NOS1 (0.71) | NOS1NOS3NOS2 | |
| SCHEMBL17318196 | 0.73 | QRFPR (0.46) | — | |
| SCHEMBL220877 | 0.70 | NOS3 (0.61) | NOS1NOS3NOS2 | |
| SCHEMBL219485 | 0.69 | NOS3 (0.64) | NOS1NOS3NOS2 | |
| SCHEMBL4018111 | 0.67 | NOS1 (0.44) | NOS1NOS3NOS2 | |
| SCHEMBL6646923 | 0.67 | GAA (0.51) | — | |
| SCHEMBL220875 | 0.67 | SYK (0.39) | NOS1FPR2XDHSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2008100376-A2 | TRUNCATION VARIANTS OF SIRT1 AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008073451-A2 | BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1910380-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1898897-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1877054-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | Sirtris Pharmaceuticals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1853590-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007008548-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006105440-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006094209-A2 | N-BENZIMIDAZOLYLALKYL-SUBSTITUTED AMIDE SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094235-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094248-A1 | ARYL-SUBSTITUTED CYCLIC SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |